UNBX
vs
S&P 500
UNBX
S&P 500
Over the past 12 months, UNBX has underperformed S&P 500, delivering a return of -96% compared to the S&P 500's +20% growth.
Stocks Performance
UNBX vs S&P 500
Performance Gap
UNBX vs S&P 500
Performance By Year
UNBX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
UNITY Biotechnology Inc
Glance View
Unity Biotechnology, Inc. operates as a biotechnology company. The company is headquartered in Brisbane California, California and currently employs 65 full-time employees. The company went IPO on 2018-05-03. The firm is engaged in developing a portfolio of programs targeting specific biological mechanisms implicated in diseases of aging. The firm is focused on creating senolytic medicines to selectively eliminate senescent cells and thereby treat diseases of aging, such as ophthalmologic diseases, with the opportunity to explore neurology and other therapeutic areas. The firm's product includes UBX1325, UBX2089 and UBX2050. UBX1325 is an advanced lead drug candidate for age-related diseases of the eye, including diabetic macular edema (DME), age-related macular degeneration (AMD), and diabetic retinopathy (DR). UBX2089, an α-Klotho hormone drug candidate, is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications. UBX2050 is investigating fully human anti-Tie2 agonist monoclonal antibody.
